Skip to content
Medical Learning Institute Inc
Home
CME Activities
Educational Series
Featured Educational Series
Oncology Communications Skills
Shedding Light on T2D
The Evolution of HCT: NMPD Series
Vaccines in Older Adults Series
Accreditation
About MLI Accreditation
About Us
About MLI
Societies and Partners
CE Coordinator Incentive Program (CECIP)
Contact Us
Medical Learning Institute Inc
Home
CME Activities
Educational Series
Featured Educational Series
Oncology Communications Skills
Shedding Light on T2D
The Evolution of HCT: NMPD Series
Vaccines in Older Adults Series
Accreditation
About MLI Accreditation
About Us
About MLI
Societies and Partners
CE Coordinator Incentive Program (CECIP)
Contact Us
Pre-Assessment
Please enable JavaScript in your browser to complete this form.
Please enable JavaScript in your browser to complete this form.
Name
*
First
Last
Email
*
NPI Number
Please provide the country in which you practice:
*
Which of the following best represents your profession?
MD/DO
NP
PA
Resident
Other
If other please describe:
What is your primary specialty?
Radiology
Neuroradiology
Imaging Specialist
Other
If other please describe:
1. What is the presumed primary mechanism underlying ARIA related to amyloid targeting therapy?
a. Direct neuronal toxicity of amyloid-beta
b. Hypoperfusion of cortical regions due to amyloid removal
c. Increased blood-brain barrier permeability
d. Ischemic injury due to amyloid-related vascular occlusion
2. A 64-year-old APOE ε4 carrier is receiving ATT and being monitored for ARIA. Which MRI sequence would you use to detect for ARIA-H?
a. Diffusion-weighted imaging (DWI)
b. Fluid-attenuated inversion recovery (FLAIR)
c. Gradient echo sequences (GRE)
d. T1-weighted post-contrast imaging
3. A 68-year-old patient with mild cognitive impairment on ATT undergoes routine MRI. FLAIR imaging reveals new focal/asymmetrical hyperintense cortical and subcortical regions without associated restricted diffusion. There is no evidence of infarction or mass effect. What do you report to the referring neurologist?
a. ARIA-E (edema/effusion)
b. Chronic small vessel disease
c. Ischemic stroke
d. Posterior reversible encephalopathy syndrome (PRES)
4. The MRI of a 57-year-old patient on ATT reveals new FLAIR hyperintensities involving multiple lobes, each < 10 cm, without significant mass effect. Interpret the MRI findings.
a. Moderate ARIA-H
b. Severe ARIA-H
c. Moderate ARIA-E
d. Severe ARIA-E
5. The referring neurologist asks for clarification on an MRI with possible ARIA-E for a patient who had been experiencing a headache while on ATT. What is the key safety consideration?
a. Confirm possible history of stroke and consider additional imaging for the next six months
b. Explain MRI findings can sometimes be ambiguous and suggest a follow-up MRI in 4 weeks
c. Recommend consulting a neuroradiologist for further interpretation before making treatment decisions
d. Suggest continued dosing and regular MRIs for monitoring due to the mild nature of the symptoms
6. Why is it important to utilize all resources, including medical alert tools, for members of the interdisciplinary care team who are managing patients receiving an ATT?
a. Identify at risk patients for appropriate imaging
b. Monitor patient adherence to medication
c. Schedule patients for recommended MRI scans
d. Track long-term patient cognitive outcomes
carrier to disease
7. How confident are you in your ability to monitor ARIA among patients with Alzheimer's disease who are receiving ATTs?
A. Completely confident
B. Fairly confident
C. Somewhat confident
D. Slightly confident
E. Not confident
Submit
Scroll to Top